

ATTACHMENT TO AMENDMENT AND REPLY

Clean Copy of Pending Claims 24, 25, 33-35, 43-45

24. (Amended) A method for the treatment of multiple sclerosis comprising administering an effective amount of naked DNA capable of expressing beta-interferon to a patient in need of such treatment.

25. (Amended) A pharmaceutical composition for the treatment of multiple sclerosis comprising an effective amount of naked DNA capable of expressing beta-interferon and a pharmaceutically acceptable carrier therefor.

33. The pharmaceutical composition of claim 25, wherein said beta-interferon is human beta-interferon.

34. The pharmaceutical composition of claim 25, wherein said beta-interferon comprises a secretory signal sequence.

35. The pharmaceutical composition of claim 25, which is suitable for administration by injection.

ATTACHMENT TO AMENDMENT AND REPLY

Clean Copy of Pending Claims 24, 25, 33-35, 43-45

43. The method of claim 24, wherein said beta-interferon is human beta-interferon.
44. The method of claim 24, wherein said beta-interferon comprises a secretory signal sequence.
45. The method of claim 24, wherein said nucleic acid is suitable for administration by injection.

Application Serial No. 09/788,552
Attorney's Docket No. 032751-053

ATTACHMENT TO AMENDMENT AND REPLY

1. Proposed Amendment to Figure 2
2. Copy of February 21, 2001 Transmittal Letter containing amendment to the Specification.